TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27919589

Group type: EXPERIMENTAL
Intervention: M + R (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: M + R + K (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + ketamine 20 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: M + R + N (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + naloxone 2 μg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: M + R + K + N (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + ketamine 20 mg + naloxone 2 μg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (Groups I, II, III)
Number of subjects: 80
Study: 24930639

Group type: EXPERIMENTAL
Intervention: SRP + MTZ (400 mg TID) + AMX (500 mg TID) for 14 days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SRP + MTZ + AMX
Number of subjects: 58

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 58
Study: 22446291

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (IT) consisting of 3 sessions of 12 repetitions of 30 seconds of exercise at very high intensity, followed by 60 seconds of complete rest.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Continuous training (CT) consisting of 45 minutes of aerobic exercise.
Number of subjects: 26
Study: 20958856

Group type: EXPERIMENTAL
Intervention: 980 nm InGasAs diode laser (power 15 W, spot size 8 mm, time 3 seconds, fluence 90 J/cm(2)) applied weekly for 9 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 980 nm InGasAs diode laser
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 17910603

Group type: COMPARATOR
Intervention: sustained-release melatonin
Number of subjects: 44
Study: 16086149

Group type: EXPERIMENTAL
Intervention: Chronic opioid therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chronic opioid therapy with antidepressant
Number of subjects: 80
Study: 12135028

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg p.o. every 12 h)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Endoscopic ethanol injection therapy
Number of subjects: 101
Study: 10396712

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiamylal 4 mg/kg
Number of subjects: 30
Study: 10468248

Group type: EXPERIMENTAL
Intervention: A4 (28,572 KIU/kg of aprotinin before surgery, followed by continuous infusion of 7,143 KIU/kg/h until the end of surgery)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: A2 (14,286 KIU/kg of aprotinin before surgery, followed by continuous infusion of 7,143 KIU/kg/h until the end of surgery)
Number of subjects: 59

Group type: COMPARATOR
Intervention: C (control group, no aprotinin)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All groups (including A2, A4, and C)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: A4
Number of subjects: 59

Group type: COMPARATOR
Intervention: A2 and C
Number of subjects: 59
Study: 1859488

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Oral azathioprine plus cyclophosphamide
Number of subjects: 111

Group type: COMPARATOR
Intervention: Prednisone only
Number of subjects: 111
Study: 6303373

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg in a slow‐release tablet once daily for 4 days and 10 mg i.v. shortly before induction of anaesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.0‐1.5 mg during anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablets and physiological saline i.v.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline i.v. instead of fentanyl or naloxone
Number of subjects: 40
Study: 31468618

Group type: EXPERIMENTAL
Intervention: Half-dose bevacizumab therapy (7.5 mg/kg every 3-4 weeks)
Number of subjects: 4
Study: 29496069

Group type: EXPERIMENTAL
Intervention: Cetuximab or Bevacizumab in combination with fluorouracil, folinic acid, and irinotecan (first-line therapy)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Presence of enlarged lymph nodes
Number of subjects: 400
Study: 26353946

Group type: EXPERIMENTAL
Intervention: Limited open carpal tunnel release
Number of subjects: 84

Group type: COMPARATOR
Intervention: Short wrist transverse open carpal tunnel release
Number of subjects: 84
Study: 25479324

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) during isometric contractions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) during recovery intervals
Number of subjects: 8
Study: 23082055

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 83

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 83
Study: 20180011

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 124
Study: 18685524

Group type: EXPERIMENTAL
Intervention: Explosive resistance training for 8 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Young training group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control groups (young and old)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 49
Study: 15833780

Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane/remifentanil
Number of subjects: 50
Study: 12431965

Group type: EXPERIMENTAL
Intervention: Marimastat 10 mg orally bid for up to 2 years
Number of subjects: 532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study: 10344347

Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 14
Study: 8950069

Group type: EXPERIMENTAL
Intervention: Guided antiarrhythmic therapy (class I, II, and III antiarrhythmic drugs)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 196
Study: 1758710

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous Infusion (CI)
Number of subjects: 20
Study: 6759059

Group type: EXPERIMENTAL
Intervention: timolol/hydrochlorothiazide/amiloride preparation
Number of subjects: 641

Group type: COMPARATOR
Intervention: cyclopenthiazide/potassium
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 641
Study: 31152039

Group type: EXPERIMENTAL
Intervention: User-centred clinical decision support (CDS) system integrated into ED clinician electronic workflow
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 28727223

Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training, 2 hours per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no abacus experience)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training
Number of subjects: 0
Study: 26031762

Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (250 μg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Chest wall strapping (CWS)
Number of subjects: 14
Study: 24214779

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg morphine sulfate
Number of subjects: 200

Group type: COMPARATOR
Intervention: 0.10 mg/kg morphine sulfate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 21745374

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Plasma exchange (PE) one volume daily for 5 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CSF protein
Number of subjects: 41
Study: 19966527

Group type: EXPERIMENTAL
Intervention: Lornoxicam (LOR) 8 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lornoxicam (LOR) 16 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline (untreated patients)
Number of subjects: 45
Study: 17445841

Group type: COMPARATOR
Intervention: Surgical treatment (early surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stereotactic aspiration technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopy for hematoma removal
Number of subjects: 0
Study: 15477634

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily
Number of subjects: 907

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg once daily
Number of subjects: 907
Study: 11581551

Group type: EXPERIMENTAL
Intervention: Creatine (CRT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Placebo (PLC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 22
Study: 9824265

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg/day for 2 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7646609

Group type: EXPERIMENTAL
Intervention: hCG supplementation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 2144941

Group type: EXPERIMENTAL
Intervention: EPA-rich pollock oil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: DHA-rich tuna or salmon-blend oils
Number of subjects: 8

Group type: COMPARATOR
Intervention: Butter diet
Number of subjects: 8
Study: 6446778

Group type: EXPERIMENTAL
Intervention: Intravenous spectinomycin hydrochloride (8 g per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Aqueous penicillin G (2.0 x 10(7) units per day, iv) plus kanamycin (1 g per day, im)
Number of subjects: 17
Study: 31522218

Group type: EXPERIMENTAL
Intervention: Sugammadex (Group S)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neostigmine + Atropine (Group N)
Number of subjects: 70
Study: 28812402

Group type: EXPERIMENTAL
Intervention: Home-based exercise program with behavioral change support
Number of subjects: 12
Study: 25979573

Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low self-efficacy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Type D personality with self-efficacy included
Number of subjects: 84
Study: 23379537

Group type: EXPERIMENTAL
Intervention: OC000459 (100 mg, twice daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21110526

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg at baseline followed by 40 mg every other week from week 1 to week 15
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19466961

Group type: EXPERIMENTAL
Intervention: High-dose UVB therapy (40% incremental doses, three times weekly)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Low-dose UVB therapy (20% incremental doses, three times weekly)
Number of subjects: 109
Study: 17699479

Group type: EXPERIMENTAL
Intervention: Hemocontrol (HC) system
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard HD
Number of subjects: 44
Study: 15107485

Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh repair
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Open mesh repair
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair of primary hernias
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Open repair of recurrent hernias
Number of subjects: 2164
Study: 11495180

Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 or 60 mg) with behavioral counseling
Number of subjects: 989

Group type: COMPARATOR
Intervention: Placebo with behavioral counseling
Number of subjects: 989
Study: 9721156

Group type: EXPERIMENTAL
Intervention: 200 mg igmesine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 25 mg igmesine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8036824

Group type: EXPERIMENTAL
Intervention: Intradermal purified chick embryo cell rabies vaccine (PCEC) alone (0.1 ml at each of two sites on days 0, 3, and 7, and at one site on days 28 and 90) (n = 81)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Intradermal PCEC with one dose of human rabies immunoglobulin (HRIG) intramuscularly at 20 IU kg‐1 on day 0 (n = 52)
Number of subjects: 133
Study: 2730948

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 0
Study: 1256687

Group type: EXPERIMENTAL
Intervention: 2‐Mercapto‐Priopionyl‐Glycine (2‐MPG) plus B12 vitamin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plus B12 vitamin
Number of subjects: 80
Study: 31295363

Group type: EXPERIMENTAL
Intervention: High-protein (PRO) diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-carbohydrate (CHO) diet
Number of subjects: 13
Study: 27959715

Group type: EXPERIMENTAL
Intervention: Inclisiran (300 mg or more, single dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inclisiran (100 mg or more, single dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inclisiran (multiple doses)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 26189484

Group type: EXPERIMENTAL
Intervention: HAL-PDT (hexyl 5‐aminolevulinate‐hydrochloride)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05% ointment (corticosteroid group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HAL-PDT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 24204065

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (weekly for up to 14 weeks)
Number of subjects: 226
Study: 20650985

Group type: EXPERIMENTAL
Intervention: Online spirometry performed by remote technicians
Number of subjects: 261

Group type: COMPARATOR
Intervention: Conventional spirometry
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Online spirometry
Number of subjects: 261
Study: 19414946

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day for 6 months
Number of subjects: 361

Group type: COMPARATOR
Intervention: Vitamin B-12 500 mcg/day
Number of subjects: 361
Study: 16888038

Group type: EXPERIMENTAL
Intervention: Brain plasticity-based training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched active control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study: 15581649

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Assistance from friends
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Understanding from friends
Number of subjects: 146
Study: 11738300

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 25
Study: 9340957

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Collar immobilisation for 3 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (50 healthy persons with the same age and sex distribution)
Number of subjects: 97
Study: 8329880

Group type: EXPERIMENTAL
Intervention: Conjoint therapy component in social-learning-based alcoholism treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social-learning-based alcoholism treatment without conjoint therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjoint treatment with high-autonomy alcoholics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment without other family members for low-autonomy alcoholics
Number of subjects: 0
Study: 3525077

Group type: EXPERIMENTAL
Intervention: Busulfan (4-6 mg/day during 4-8 weeks, with re-administration at relapse)
Number of subjects: 293

Group type: COMPARATOR
Intervention: 32P (0.5-1 mCi/10 kg at diagnosis and for each overt relapse)
Number of subjects: 293
Study: 29072342

Group type: EXPERIMENTAL
Intervention: Protected areas
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Long-term data analysis
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Short-term data analysis
Number of subjects: 5000
Study: 27403046

Group type: EXPERIMENTAL
Intervention: Ferric sulfate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Buffered glutaraldehyde
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 90
Study: 24299006

Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dycal
Number of subjects: 80

Group type: COMPARATOR
Intervention: Small pulp exposure areas (<5 mm²)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Large pulp exposure areas (>5 mm²)
Number of subjects: 80
Study: 22456602

Group type: EXPERIMENTAL
Intervention: Six times per week hemodialysis (Daily Trial)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Three times per week hemodialysis (Daily Trial)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Six times per week nocturnal hemodialysis (Nocturnal Trial)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Three times per week conventional hemodialysis (Nocturnal Trial)
Number of subjects: 332
Study: 19863578

Group type: EXPERIMENTAL
Intervention: Carisbamate 400 mg/day
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Carisbamate 200 mg/day
Number of subjects: 1127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1127
Study: 18034847

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 40
Study: 15826611

Group type: EXPERIMENTAL
Intervention: Clarified appearance question (e.g., 'What does the sponge look like?')
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard appearance-reality task
Number of subjects: 3
Study: 14587161

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 1

Group type: COMPARATOR
Intervention: Classical catecholamines (dopamine and dobutamine)
Number of subjects: 1
Study: 10821721

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg bid
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg bid
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 8875683

Group type: EXPERIMENTAL
Intervention: Furosemide (15 mg/kg)
Number of subjects: 94
Study: 1999935

Group type: EXPERIMENTAL
Intervention: International normalized ratio of 2.0 to 2.99 (Group A)
Number of subjects: 99

Group type: COMPARATOR
Intervention: International normalized ratio of 3.0 to 4.5 (Group B)
Number of subjects: 99
Study: 6203596

Group type: EXPERIMENTAL
Intervention: Combination of dextran 70 and dihydroergotamine (DHE)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Dextran 70 alone
Number of subjects: 259
Study: 31579904

Group type: EXPERIMENTAL
Intervention: empagliflozin 10 or 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 29958127

Group type: EXPERIMENTAL
Intervention: iTAB (individualized texting for adherence building); n=50
Number of subjects: 75

Group type: COMPARATOR
Intervention: Active control; n=25
Number of subjects: 75
Study: 26993374

Group type: EXPERIMENTAL
Intervention: Meat phantom model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh-frozen human cadaver
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training and deliberate feedback
Number of subjects: 0
Study: 24646104

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months (n = 500)
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo (n = 511)
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Oral alendronate 35 mg weekly (n = 251)
Number of subjects: 1262
Study: 22450015

Group type: EXPERIMENTAL
Intervention: Intercostal nerve block with ropivacaine (0.5% combined with epinephrine)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (without intercostal nerve block)
Number of subjects: 50
Study: 20222915

Group type: EXPERIMENTAL
Intervention: lesogaberan (0.8 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: baclofen (40 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 18019850

Group type: EXPERIMENTAL
Intervention: d‐threo‐methylphenidate (d‐MPH) 5‐15 mg twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15692131

Group type: EXPERIMENTAL
Intervention: Reclining hospital chair
Number of subjects: 132

Group type: COMPARATOR
Intervention: Gurney
Number of subjects: 132
Study: 11991884

Group type: EXPERIMENTAL
Intervention: Negative expiratory pressure (NEP) of -10 cm H2O
Number of subjects: 6

Group type: COMPARATOR
Intervention: No negative expiratory pressure (baseline)
Number of subjects: 6
Study: 9505155

Group type: EXPERIMENTAL
Intervention: 20 g SPP
Number of subjects: 7

Group type: COMPARATOR
Intervention: 20 g SPP (raw)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20 g SPP (baked into bread)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 20 g lactulose
Number of subjects: 7

Group type: COMPARATOR
Intervention: 20 g oat bran
Number of subjects: 7

Group type: COMPARATOR
Intervention: 20 g wheat bran
Number of subjects: 7

Group type: COMPARATOR
Intervention: 180 g wheat flour (control bread)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 180 g wheat flour with 20 g raw SPP (bread)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 180 g wheat flour with 20 g SPP (baked bread)
Number of subjects: 7
Study: 8546510

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 800 micrograms/day
Number of subjects: 13
Study: 2507265

Group type: EXPERIMENTAL
Intervention: NPH insulin plus 10 mg glyburide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin plus placebo
Number of subjects: 20
Study: 799563

Group type: EXPERIMENTAL
Intervention: Timolol alone (10 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + amiloride (25 mg + 2-5 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Timolol + hydrochlorothiazide + amiloride (10 mg + 25 mg + 2-5 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54